Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ACE | P12821 | 2/20 | 0.33 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL690215 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL689733 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL3674503 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL19080644 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL689912 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL1303907 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL7882438 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| SCHEMBL8989612 | 1.00 | ATM (0.59) | ATMPIK3CDGAAALDH1A1ACE | |
| Hydrochloric Acid SCHEMBL350474 | 0.98 | ATM (0.57) | ATMPIK3CDGAAALDH1A1ACE | |
| Hydrochloric Acid SCHEMBL2147938 | 0.98 | ATM (0.57) | ATMPIK3CDGAAALDH1A1ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 233 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | claimed |
| US-20250147048-A1 | METHODS OF DIAGNOSTIC SCREENING AND EARLY DETECTION OF ADENOMYOSIS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-05-08 | — | — | US | claimed |
| CN-115656161-A | Phthalic dicarboxaldehyde disinfectant concentration detection indicator card and preparation method thereof | 利康医药科技江苏有限公司 | 2023-01-31 | — | — | CN | claimed |
| US-5665371-A | SIDE EFFECT REDUCTION | HOERRMANN WILHELM (DE) | 1997-09-09 | — | — | US | claimed |
| EP-0223850-A1 | MEDICINES WHICH CONTAIN DERIVATIVES OF PROLINE OR HYDROXYPROLINE. | HOERMANN WILHELM | 1987-06-03 | — | — | EP | claimed |
| WO-1986007053-A1 | MEDICINES WHICH CONTAIN DERIVATIVES OF PROLINE OR HYDROXYPROLINE | HOERRMANN WILHELM (DE) | 1986-12-04 | — | — | WO | claimed |
| US-12390446-B2 | Proline-based neuropeptide FF receptor modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2025-08-19 | — | — | US | disclosed |
| WO-2025123045-A1 | PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250147048-A1 | METHODS OF DIAGNOSTIC SCREENING AND EARLY DETECTION OF ADENOMYOSIS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-05-08 | — | — | US | disclosed |
| US-20240376073-A1 | QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-14 | — | — | US | disclosed |
| US-20240254140-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2024-08-01 | — | — | US | disclosed |
| EP-4405352-A1 | NEW COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2024-07-31 | — | — | EP | disclosed |
| US-20240246961-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-07-25 | — | — | US | disclosed |
| US-4931352-A | Antifungal fermentation product | MERCK & CO., INC. (US) | 1990-06-05 | — | — | US | disclosed |
| EP-0223850-B1 | MEDICINES WHICH CONTAIN DERIVATIVES OF PROLINE OR HYDROXYPROLINE | Hoerrmann, Wilhelm, Dr. (DE) | 1990-04-11 | — | — | EP | disclosed |
| EP-0359529-A1 | Method for the control of pneumocystis carinii | MERCK & CO. INC. (US) | 1990-03-21 | — | — | EP | disclosed |
| EP-0311194-A2 | Process for antifungal fermentation product and culture | MERCK & CO. INC. (US) | 1989-04-12 | — | — | EP | disclosed |
| EP-0311193-A2 | Antifungal fermentation product | MERCK & CO. INC. (US) | 1989-04-12 | — | — | EP | disclosed |
| EP-0223850-A1 | MEDICINES WHICH CONTAIN DERIVATIVES OF PROLINE OR HYDROXYPROLINE. | HOERMANN WILHELM | 1987-06-03 | — | — | EP | disclosed |
| WO-1986007053-A1 | MEDICINES WHICH CONTAIN DERIVATIVES OF PROLINE OR HYDROXYPROLINE | HOERRMANN WILHELM (DE) | 1986-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390446-B2 | Proline-based neuropeptide FF receptor modulators | NPFFR1, NPFFR2, NPBWR1 | ATM 4858/4885PIK3CD 4101/4885GAA 3569/4885 |
| US-20240254140-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | C3AR1, LTB4R, C5 | ATM 3666/4885PIK3CD 3151/4885GAA 2465/4885 |
| US-20240246961-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, ATXN10, ATXN2L | ATM 2905/4885PIK3CD 2434/4885GAA 87/4885 |
| US-20240376073-A1 | QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CFTR, HRH1, HRH4 | ATM 2562/4885PIK3CD 2003/4885GAA 797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.